Market overview
The global continuous flow bioreactors market is worth USD 549 mn in 2026 and is forecast to reach USD 1.6 bn by 2036, growing at a 11.0% CAGR. United States is the largest country market and Pilot and process development is the largest by scale segment.
| Scope | Bioreactor systems that run cell culture with continuous perfusion or continuous feed and harvest, including single-use perfusion units, alternating tangential flow filters and controllers. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 490 mn |
| Value 2026 | USD 549 mn |
| Value 2036 | USD 1.6 bn |
| CAGR 2026-2036 | 11.0% |
| Volume 2026 | 3,584 units |
| Volume 2036 | 10,176 units |
| Average price 2026 | USD 153,100 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Continuous Flow Bioreactors market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 549 mn |
| 2027 | USD 609 mn |
| 2028 | USD 676 mn |
| 2029 | USD 751 mn |
| 2030 | USD 833 mn |
| 2031 | USD 925 mn |
| 2032 | USD 1.0 bn |
| 2033 | USD 1.1 bn |
| 2034 | USD 1.3 bn |
| 2035 | USD 1.4 bn |
| 2036 | USD 1.6 bn |
Continuous Flow Bioreactors market segmentation
By scale
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pilot and process development | 38.0% | 34.5% | USD 209 mn | 9.9% |
| Clinical scale | 36.0% | 37.3% | USD 198 mn | 11.4% |
| Commercial scale | 26.0% | 28.2% | USD 143 mn | 11.9% |
By use
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Monoclonal antibodies | 44.0% | 38.9% | USD 241 mn | 9.6% |
| Cell and gene therapy | 24.0% | 30.3% | USD 132 mn | 13.6% |
| Viral vectors and vaccines | 20.0% | 20.2% | USD 110 mn | 11.1% |
| Other biologics | 12.0% | 10.6% | USD 66 mn | 9.6% |
By format
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Single-use systems | 66.0% | 71.9% | USD 362 mn | 11.9% |
| Hybrid systems | 12.0% | 11.4% | USD 66 mn | 10.5% |
| Stainless steel systems | 22.0% | 16.7% | USD 121 mn | 8.0% |
By material
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Single use | 52.0% | 60.0% | USD 285 mn | 12.6% |
| Stainless steel | 36.0% | 28.0% | USD 198 mn | 8.2% |
| Glass and hybrid | 12.0% | 12.0% | USD 66 mn | 11.0% |
By application
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Monoclonal antibodies | 50.0% | 46.0% | USD 274 mn | 10.1% |
| Vaccines | 20.0% | 17.0% | USD 110 mn | 9.2% |
| Cell and gene therapy | 14.0% | 22.0% | USD 77 mn | 16.1% |
| Others biologics | 16.0% | 15.0% | USD 88 mn | 10.3% |
Top 25 countries for continuous flow bioreactors by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 89.5% of 2026 revenue and the 25 countries below together hold 97.2%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 198 mn | 36.0% | USD 531 mn | 10.4% |
| 2 | Germany | USD 55 mn | 10.0% | USD 142 mn | 10.0% |
| 3 | China | USD 55 mn | 10.0% | USD 201 mn | 13.9% |
| 4 | Switzerland | USD 33 mn | 6.0% | USD 89 mn | 10.4% |
| 5 | South Korea | USD 33 mn | 6.0% | USD 106 mn | 12.4% |
| 6 | Ireland | USD 27 mn | 5.0% | USD 73 mn | 10.3% |
| 7 | Japan | USD 27 mn | 5.0% | USD 67 mn | 9.3% |
| 8 | United Kingdom | USD 22 mn | 4.0% | USD 59 mn | 10.4% |
| 9 | Singapore | USD 22 mn | 4.0% | USD 67 mn | 11.8% |
| 10 | India | USD 19 mn | 3.5% | USD 67 mn | 13.3% |
| 11 | Denmark | USD 7.3 mn | 1.3% | USD 19 mn | 10.2% |
| 12 | Netherlands | USD 6.0 mn | 1.1% | USD 16 mn | 10.3% |
| 13 | Belgium | USD 5.8 mn | 1.1% | USD 15 mn | 10.2% |
| 14 | Sweden | USD 4.4 mn | 0.8% | USD 12 mn | 10.3% |
| 15 | Austria | USD 3.3 mn | 0.6% | USD 8.9 mn | 10.4% |
| 16 | Brazil | USD 2.7 mn | 0.5% | USD 8.1 mn | 11.4% |
| 17 | Taiwan | USD 2.6 mn | 0.5% | USD 8.0 mn | 11.7% |
| 18 | Israel | USD 2.3 mn | 0.4% | USD 6.2 mn | 10.5% |
| 19 | Canada | USD 1.9 mn | 0.3% | USD 5.1 mn | 10.3% |
| 20 | Italy | USD 1.6 mn | 0.3% | USD 4.2 mn | 10.2% |
| 21 | Spain | USD 1.1 mn | 0.2% | USD 3.0 mn | 10.4% |
| 22 | Australia | USD 0.99 mn | 0.2% | USD 2.6 mn | 10.4% |
| 23 | Poland | USD 0.71 mn | 0.1% | USD 2.2 mn | 11.8% |
| 24 | Mexico | USD 0.66 mn | 0.1% | USD 2.0 mn | 11.9% |
| 25 | Russia | USD 0.49 mn | 0.09% | USD 1.6 mn | 12.2% |
| Rest of world | USD 16 mn | 2.8% | USD 41 mn | 10.2% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Sartorius
- Cytiva
- Thermo Fisher Scientific
- Merck KGaA
Group 2: Regional and specialist players
- Repligen
- Eppendorf
- Getinge
- ABEC
- Zeta Group
Group 3: Emerging and niche players
- Applikon Biotechnology
- PBS Biotech
- Cellexus
- Celltainer Biotech
- Kuhner
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the continuous flow bioreactors market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 11.0% is calculated from the resulting values.
The market is divided by scale, by use, by format, by material, by application. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the continuous flow bioreactors market?
The global continuous flow bioreactors market is estimated at USD 490 mn in 2025 and USD 549 mn in 2026.
How fast will the continuous flow bioreactors market grow?
It is forecast to reach USD 1.6 bn by 2036, a compound annual growth rate of 11.0% from 2026, an increase of USD 1.0 bn.
Which country is the largest market for continuous flow bioreactors?
United States is the largest market by revenue at USD 198 mn in 2026, 36.0% of the global total. The three largest countries together hold 56.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 13.9% a year from 2026 to 2036.
Which continuous flow bioreactors segment is largest?
In the by scale split, Pilot and process development is the largest segment with 38.0% of 2026 revenue.
Who are the leading continuous flow bioreactors companies?
Global leaders include Sartorius, Cytiva, Thermo Fisher Scientific, Merck KGaA.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Reproductive Toxicity StudiesUSD 549 mn · 5.3% CAGR
- Shelf-Stable Clinical MealUSD 551 mn · 6.5% CAGR
- Widefield Imaging SystemsUSD 551 mn · 6.5% CAGR
- Wound Irrigation SystemsUSD 551 mn · 5.8% CAGR
- Pharmaceutical Omega-3 APIUSD 546 mn · 5.5% CAGR
- Cancer Survivorship NutritionUSD 554 mn · 6.5% CAGR
- Micro Balloon CatheterUSD 554 mn · 6.2% CAGR
- Bone Densitometer DevicesUSD 543 mn · 4.8% CAGR
← Comparator Sourcing Continuous Peripheral Nerve Block Catheter →